M&A / Deals Alzheimer’s biotech Korsana to go public via reverse merger PharmaphorumBy merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.M&A / DealsNeuroscienceRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsNext: Merck KGaA acquires JSR chromatography business Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
